The clinical trial sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd. aims to evaluate the efficacy of dental pulp mesenchymal stem cells in treating severe pneumonia caused by COVID-19. Given the ongoing global health crisis and the urgent need for effective therapies, this trial could position CAR-T as a key player in the regenerative medicine space, particularly in the context of viral pneumonia treatments. The market for COVID-19 therapeutics remains competitive, with numerous players exploring various modalities, including monoclonal antibodies, antivirals, and cell therapies. Successful outcomes could lead to significant commercial opportunities, especially if the therapy demonstrates a favorable safety and efficacy profile compared to existing treatments. Diligence should focus on regulatory pathways, potential partnerships, and the scalability of DPMSC production.